Mereo Biopharma Group Plc (MPH):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Mereo Biopharma Group Plc (MPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8148
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Mereo Biopharma Group Plc (Mereo), formerly Mereo Biopharma Group Ltd is a specialty bio-pharmaceutical company which develops novel medicines for the treatment of rare and specialty diseases. The company’s pipeline products include BPS-804, which is used for the treatment of brittle bone syndrome; and BCT-197, an orally active p38 MAP kinase inhibitor developed for acute exacerbations of chronic obstructive pulmonary disease. Mereo also offers BGS-649, an orally active aromatase inhibitor developed for the treatment of obese men with hypogonadotrophic hypogonadism; and AZD-9668 , an oral neutrophil elastase inhibitor for the treatment of alpha-1 antitrypsin deficiency. The company collaborates with biotechnology and pharmaceutical companies. Mereo is headquartered in London, the UK.

Mereo Biopharma Group Plc (MPH) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Mereo Biopharma Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Mereo Biopharma Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Mereo Biopharma Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Mereo Biopharma Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Mereo Biopharma Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Mereo Biopharma Group Plc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Mereo BioPharma Acquires Clinical Assets from Novartis 11
Licensing Agreements 12
Mereo Biopharma Enters into Licensing Agreement with AstraZeneca 12
Equity Offering 13
Mereo Biopharma Postpones Public Offering of ADS 13
Mereo Biopharma Withdraws Private Placement of Shares 15
Mereo Biopharma Plans to Raise Funds through Public Offering of Shares 17
Mereo BioPharma Raises USD18.8 Million in Private Placement of Shares 18
Mereo Biopharma Raises USD17.3 Million in Private Placement of Shares 19
Mereo BioPharma Raises USD119 Million in Private Placement of Shares 20
Mereo Biopharma Group Plc – Key Competitors 21
Mereo Biopharma Group Plc – Key Employees 22
Mereo Biopharma Group Plc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Aug 08, 2018: Mereo BioPharma interim results for the six month period ended June 30, 2018 24
Mar 23, 2018: Mereo BioPharma Announces Preliminary Results for the Year Ended December 31, 2017 26
Aug 08, 2017: Mereo BioPharma: Unaudited interim results for the period ended 30 June 2017 27
Feb 27, 2017: Mereo BioPharma Announces Preliminary results for the year ended 31 December 2016 28
Corporate Communications 29
Jan 12, 2017: Mereo BioPharma: Directorate update 29
Jan 12, 2017: Mereo BioPharma Group: Directorate update 30
Product News 31
02/20/2017: Mereo BioPharma: BPS-804 accepted for EMA Adaptive Pathways programme 31
Product Approvals 32
Nov 13, 2017: Mereo Receives EMA PRIME Designation for BPS-804 to Treat Osteogenesis Imperfecta 32
Clinical Trials 33
Mar 19, 2018: Mereo BioPharma Announces Positive Top-Line Results from Phase 2b Study of BGS-649 for the Treatment of Hypogonadotropic Hypogonadism in Obese Men 33
Sep 05, 2017: Completion of Patient Enrolment in Phase 2b dose-confirmation study of BGS-649 for the treatment of hypogonadotropic hypogonadism 35
May 04, 2017: Initiation of BPS-804 potentially pivotal Phase 2b study in patients with osteogenesis imperfecta, an orphan disease 36
Mar 07, 2017: Mereo BioPharma Group: Positive recommendation for BGS-649 Phase 2b trial following planned IDMC interim analysis 37
Other Significant Developments 38
Dec 13, 2017: Mereo BioPharma Group Announces Business Update 38
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Mereo Biopharma Group Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Mereo Biopharma Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Mereo Biopharma Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Mereo Biopharma Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Mereo Biopharma Group Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Mereo Biopharma Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Mereo BioPharma Acquires Clinical Assets from Novartis 11
Mereo Biopharma Enters into Licensing Agreement with AstraZeneca 12
Mereo Biopharma Postpones Public Offering of ADS 13
Mereo Biopharma Withdraws Private Placement of Shares 15
Mereo Biopharma Plans to Raise Funds through Public Offering of Shares 17
Mereo BioPharma Raises USD18.8 Million in Private Placement of Shares 18
Mereo Biopharma Raises USD17.3 Million in Private Placement of Shares 19
Mereo BioPharma Raises USD119 Million in Private Placement of Shares 20
Mereo Biopharma Group Plc, Key Competitors 21
Mereo Biopharma Group Plc, Key Employees 22
Mereo Biopharma Group Plc, Subsidiaries 23

List of Figures
Mereo Biopharma Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Mereo Biopharma Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Mereo Biopharma Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Mereo Biopharma Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Mereo Biopharma Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Mereo Biopharma Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Mereo Biopharma Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Mereo Biopharma Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Mereo Biopharma Group Plc (MPH):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Versantis AG-製薬・医療分野:企業M&A・提携分析
    Summary Versantis AG (Versantis), is a preclinical stage pharmaceutical company which offers new medicines and diagnostics for treating liver diseases. It’s lead pipeline product VS-01, capable of removing toxic agents from the organism and save patients from prescription and illicit drug overdoses. …
  • Teck Resources Ltd:戦略・SWOT・企業財務分析
    Teck Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Teck Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • IGas Energy PLC (IGAS):企業の財務・戦略的SWOT分析
    IGas Energy PLC (IGAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Rottneros AB (RROS):企業の財務・戦略的SWOT分析
    Rottneros AB (RROS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Sumitomo Metal Mining Co Ltd:戦略・SWOT・企業財務分析
    Sumitomo Metal Mining Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Metal Mining Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Summit Hotel Properties Inc:企業のM&A・事業提携・投資動向
    Summit Hotel Properties Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Summit Hotel Properties Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • TTM Technologies Inc:企業の戦略・SWOT・財務分析
    TTM Technologies Inc - Strategy, SWOT and Corporate Finance Report Summary TTM Technologies Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Immupharma Plc (IMM):製薬・医療:M&Aディール及び事業提携情報
    Summary ImmuPharma Plc (ImmuPharma) develops novel drugs for the treatment of serious medical conditions with unmet medical need. ImmuPharma develops drugs for the treatment of lupus, cancer, moderate to severe pain, highly resistant hospital-acquired infections such as methicillin-resistant staphyl …
  • Exact Holding N.V.:企業の戦略的SWOT分析
    Exact Holding N.V. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • PolyPid Ltd-医療機器分野:企業M&A・提携分析
    Summary PolyPid Ltd (PolyPid) is a clinical stage pharmaceutical company that develops, manufactures and commercialize drugs for extended release and local delivery. The company develops its products using PLEX (Polymer-Lipid Encapsulation MatriX) platform, which helps in products. PolyPid’s pipelin …
  • Sisaf Ltd-医療機器分野:企業M&A・提携分析
    Summary Sisaf Ltd (Sisaf) is a drug delivery company which designs and develops topical delivery systems for cosmetic, medical, and skin care applications. The company manufactures and markets products and drug delivery solutions using ProSilic, a nano-silicon technology platform. It offers ProSilli …
  • Generex Biotechnology Corp (GNBT):製薬・医療:M&Aディール及び事業提携情報
    Summary Generex Biotechnology Corp (Generex) carries out the research, development and commercialization of drug delivery systems and technologies. It developed a proprietary platform technology to deliver drugs into the human body through the oral cavity. The company’s proprietary liquid formulatio …
  • Elmet Technologies, Inc.:企業の戦略・SWOT・財務情報
    Elmet Technologies, Inc. - Strategy, SWOT and Corporate Finance Report Summary Elmet Technologies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Tempur Sealy International Inc (TPX):企業の財務・戦略的SWOT分析
    Tempur Sealy International Inc (TPX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Moog Inc.:企業の戦略・SWOT・財務情報
    Moog Inc. - Strategy, SWOT and Corporate Finance Report Summary Moog Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • UCB S.A.:企業の戦略・SWOT・財務分析
    UCB S.A. - Strategy, SWOT and Corporate Finance Report Summary UCB S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Galderma SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Galderma SA (Galderma), a subsidiary of Nestle SA, is a pharmaceutical company that develops and markets drugs, medical dermatology solutions and therapeutic skin care products for the treatment of hair, nail, and skin diseases. Galderma offers products for the treatment of skin conditions s …
  • Cytokinetics Inc (CYTK):製薬・医療:M&Aディール及び事業提携情報
    Summary Cytokinetics Inc (Cytokinetics) is a late stage biopharmaceutical company, which discovers, develops, and commercializes muscle activators for the treatment of diseases associated with reduced muscle performance. The company’s pipeline encompasses omecamtiv mecarbil, a novel cardiac myosin a …
  • ANS Group Plc:企業の戦略的SWOT分析
    ANS Group Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Shimadzu Corp (7701)
    Shimadzu Corp (7701) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company

◆H&Iグローバルリサーチ株式会社のお客様(例)◆